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Nonsyndromic cleft lip with/without cleft palate (nsCL/P) and nonsyndromic cleft palate only (nsCPO) are the most frequent subphe-
notypes of orofacial clefts. A common syndromic form of orofacial clefting is Van der Woude syndrome (VWS) where individuals have
CL/P or CPO, often but not always associated with lower lip pits. Recently, ~5% of VWS-affected individuals were identified with mu-
tations in the grainy head-like 3 gene (GRHL3). To investigate GRHL3 in nonsyndromic clefting, we sequenced its coding region in 576
Europeans with nsCL/P and 96 with nsCPO. Most strikingly, nsCPO-affected individuals had a higher minor allele frequency for
rs41268753 (0.099) than control subjects (0.049; p¼ 1.243 102). This associationwas replicated in nsCPO/control cohorts from Latvia,
Yemen, and the UK (pcombined ¼ 2.63 3 105; ORallelic ¼ 2.46 [95% CI 1.6–3.7]) and reached genome-wide significance in combination
with imputed data from a GWAS in nsCPO triads (p ¼ 2.73 3 109). Notably, rs41268753 is not associated with nsCL/P (p ¼ 0.45).
rs41268753 encodes the highly conserved p.Thr454Met (c.1361C>T) (GERP ¼ 5.3), which prediction programs denote as deleterious,
has a CADD score of 29.6, and increases protein binding capacity in silico. Sequencing also revealed four novel truncating GRHL3mu-
tations including two that were de novo in four families, where all nine individuals harboring mutations had nsCPO. This is important
for genetic counseling: given that VWS is rare compared to nsCPO, our data suggest that dominant GRHL3mutations are more likely to
cause nonsyndromic than syndromic CPO. Thus, with rare dominant mutations and a common risk variant in the coding region, we
have identified an important contribution for GRHL3 in nsCPO.Orofacial clefts are among the most common congenital
malformations in humans.1 The two common distinct
cleft phenotypes are cleft lip with or without cleft palate
(CL/P) and cleft palate only (CPO).2 These two phenotypes
most often occur without additional clinical features and
are described as nonsyndromic clefts (i.e., nsCL/P and
nsCPO) that present with a multifactorial etiology
including contributions from both diverse genetic and
environmental factors.2 Based on previous epidemiolo-
gical observations and also genetic findings, nsCL/P and
nsCPO are considered to have only very limited overlap
in terms of their genetic etiology. This is further supported
by findings from genome-wide association studies
(GWASs) that have identified 15 risk loci for nsCL/P3–9
although no genome-wide significant findings have been
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a region on 9q21, which had been initially identified in a
linkage study of nonsyndromic clefting families.11,12 Sub-
sequent fine mapping identified two SNPs around FOXE1
(MIM: 602617) that potentially accounted for linkage to
both nsCL/P and nsCPO, with the larger effect sizes in
nsCL/P.13 This finding was independently confirmed,14
although association with nsCPO did not reach genome-
wide significance.
CL/P and CPO can also occur in the context of complex
malformation syndromes. One of the most common of
these is Van der Woude syndrome (VWS [MIM: 119300]).
Mutations in the interferon regulatory factor 6 (IRF6)
gene (MIM: 607199) account for ~70% of individuals
with VWS, and recently grainy head-like 3 (GRHL3 [MIM:
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Individuals with VWS have either a CL/P or a CPO, with
pits of the lower lip being the sole additional symptom dis-
tinguishing individuals from those with nonsyndromic
clefts. Lip pits seen in VWS-affected individuals have an
incomplete penetrance or can be subtle and sometimes
difficult to recognize, especially after surgical treatment.
Thus, individuals with an IRF6 or GRHL3 mutation might
sometimes be considered to have a nonsyndromic cleft.
Consequently, several studies have screened individuals
with apparently nonsyndromic clefting for IRF6mutations
to investigate their prevalence.16,17 These studies showed
that the majority of individuals carrying IRF6 mutations
but classified as nonsyndromic turned out to have lip
pits when a posteriori reviewed, i.e., they were misdiag-
nosed VWS.17 Only a minority (0.24%–0.44% of the
families) remained truly nonsyndromic from a clinical
perspective. No such studies have yet been presented for
GRHL3. Of note, among individuals with GRHL3 muta-
tions, CPO is more frequent, while both CL/P and lip
pits are less frequent compared to individuals with IRF6
mutations.15 Therefore, we speculated that individuals
harboring GRHL3 mutations would be even more likely
to ‘‘mimic’’ nonsyndromic clefts.
Based on this hypothesis, we evaluated a large sample
of individuals with nonsyndromic clefts for mutations
in GRHL3. Of note, recent calculations on genic intolerance
towardmutations in data from the ExomeAggregationCon-
sortium (ExAC)18 reveals thatGRHL3 is extremely intolerant
toward loss-of-function mutations (pLI¼ 1) and also shows
some degree of intolerance toward missense mutations.
The GRHL3 coding region was Sanger sequenced in a total
of 672 unrelated individuals with clefting of Central Euro-
pean origin with either nsCL/P (576 individuals) or nsCPO
(96 individuals). This studywas approvedby theEthicsCom-
mittee of the Medical Faculty of the University of Bonn.
Informed consentwas obtained fromall participants or their
legal representatives, which also applies to all further sam-
ples used throughout this study. For these, study approval
wasobtained fromthe respective institutional reviewboards.
Sequencing was performed at Macrogen using 13 ampli-
cons that targeted all 18 exons and UTRs of the four
known transcripts of GRHL3 (Table S1). Data analysis was
performed with the SeqMan pro software provided by
DNASTAR. Rare variants with minor allele frequencies
(MAF) < 1% were subsequently confirmed in-house using
BigDye v3.1 kit and an ABI 3130XL Capillary Sequencer.
Sequencing revealed 30 variants in total, 18 of which
were rare in our sample (Table S2). Twelve variants were
more frequent (MAFR 1%; Table S3) and already assigned
rs numbers. For all of the more common variants, MAFs
were comparable between individuals with clefts and Euro-
pean control subjects in public databases (ExAC, 1000
Genomes,19 Exome Variant Server [EVS], and Genome of
the Netherlands [GoNL];20 Web Resources, Table S3).
However, when dividing the cleft cohort according to cleft
phenotype (nsCL/P or nsCPO), one of the variants,
rs41268753, was observed to have a significantly higher756 The American Journal of Human Genetics 98, 755–762, April 7, 2MAF of 0.099 in individuals with nsCPO compared to con-
trol subjects. The highest MAF for this variant among the
four control cohorts was reported in the GoNL dataset
(genotype distribution 0/41/457, MAF ¼ 0.041, Armitage
trend test for association with rs41268753: p ¼ 5.79 3
104). Given the population-specific occurrence of rare
and low-frequency variants and to rule out population
stratification,21 we genotyped rs41268753 in an additional
267 controls of Central European origin, using a KASP
assay on demand (LGC; Table 1). In this dataset, the MAF
for rs41268753 was 0.049 and therefore slightly higher
than indicated in the public databases, although the asso-
ciation remained significant (p ¼ 0.0124, Table 1).
In order to replicate our finding, we evaluated three inde-
pendent nsCPO case-control cohorts for association of
rs41268753 (Table 1). These included (1) 47 individuals
withnsCPOand187 control subjects fromYemen, (2) 94 in-
dividuals with nsCPO and 177 control subjects of European
ethnicity recruited in the London area, and (3) 51 individ-
uals with nsCPO and 94 control subjects from Latvia. In
each of the samples, an association was found (p < 0.1),
and the combination of the initial sample with the replica-
tion samples by fixed effects meta analysis22 resulted in a
pcombined of 2.63 3 10
5 with an ORallelic of 2.5 (95% CI
1.6–3.7, Table 1). To further evaluate this finding, we
imputed GWAS data from nsCPO triads of European
origin10 that we had downloaded from dbGaP upon
approved data access. Imputation was performed using
IMPUTE2,23 and analysis of imputed data was performed
according to the FBATdosage method.24 The imputed data
(p ¼ 1.18 3 104) confirmed our previous observation
gained in the genotyped samples for rs41268753. Com-
bining the genotyped datasets with the imputation by the
Z score method24 led to a genome-wide significant associa-
tion signal for rs41268753 in nsCPO (p ¼ 2.733 109).
Next, we evaluated rs41268753 in individuals with a
submucous palatal cleft, which is considered a mild
subphenotype of CPO. Of note, dominant GRHL3 muta-
tions have previously been described in individuals with
submucous palatal clefts,15 and one individual harboring a
truncatingGRHL3mutation in the present study had a sub-
mucous cleft palate. We genotyped 116 Central European
individuals with nonsyndromic submucous palatal clefts
using PCR followed by direct genotyping, but we did not
find a significant association when compared to the 267
Central European control subjects (p¼ 0.94). Given the sta-
tistical power to detect an association of the effect size found
in the nsCPO sample (0.87, calculated according to Jackson
et al.25),weconclude that, although rareGRHL3variants can
lead to a submucous palatal cleft, rs41268753 does not
significantly contribute to this subphenotype of CPO.
The newly identified susceptibility variant, rs41268753,
is present in all four known isoforms of GRHL3 and
encodes the p.Thr454Met (c.1361C>T)missense alteration
(GenBank: NP_937817.3), located between the DNA bind-
ing and the dimerization domain of GRHL3.15 Analysis of
rs41268753 via the Variant Effect Predictor generated016
Table 1. Single Marker Association Results of rs41268753 in Different Replication Cohorts and Combined Analysis
Sample
Case Subjects Control Subjects
Test
Statistics p Value
Allelic RR
(95%CI)
Genotyping
Method Sample Description
Genotype
Distribution MAF
Genotype
Distribution MAF
Central
Europeans
0/19/77 0.099 1/24/242 0.049 6.26 1.24 3 102 2.15 (1.16–3.97) KASP assay on
demand
case subjects: Mangold
et al.;37 control subjects:
Birnbaum et al.4
Yemen 0/6/41 0.064 0/10/177 0.027 3.25 7.16 3 102 2.48 (0.88–7.01) KASP assay on
demand
Aldhorae et al.38
Latvia 0/10/41 0.098 0/3/91 0.016 10.92 9.53 3 104 6.70 (1.80–24.95) TaqMan
genotyping
Nikopensius et al.39
Europeans
from London
1/11/82 0.069 1/10/166 0.034 3.098 7.84 3 102 2.12 (0.95–4.74) Sanger
sequencing
case subjects;a control
subjects: Apostolidou
et al.40
Combined – – – – – 2.63 3 105 2.46 (1.62–3.74)
Combination
with European
trios (dbGaP)b
– – – – – 2.73 3 109 GWAS Beaty et al.10
Abbreviations are as follows: MAF, minor allele frequency; RR, relative risk; CI, confidence interval.
aThe patient cohort consisted of 136 individuals with nonsyndromic CPO (including 94 European individuals), who were clinically evaluated and treated at the
North Thames Regional Cleft Centre based at Great Ormond Street Children’s Hospital, London.
bThe datasets used for the analyses described in this manuscript were obtained from dbGaP: phs000094.v1.p1. Genotypes were imputed using IMPUTE2 and
analyzed using the FBATdosage method in which the mean of transmitted allele dosages is compared to the mean of non-transmitted allele dosages. The
mean of transmitted allele dosages estimates the allele frequency in affected children (for rs41268753; 0.093) whereas the mean of non-transmitted allele dosages
estimates the frequency in non-transmitted parental alleles (rs41267853: 0.036). For rs41268753, this reveals p ¼ 1.18 3 104 in the European nsCPO trios.strong evidence for deleteriousness (‘‘probably damaging’’
by PolyPhen-2 and ‘‘deleterious’’ by SIFT, MutationTaster,
Provean, and Condel). Moreover, the variant occurs at a
highly conserved nucleotide position (GERP score 5.27)
and the CADD score is reported to be 29.6. In the absence
of any experimental structures of theGRHL3protein,we at-
tempted to use Swiss-Model26 for protein structure homol-
ogy modeling. However, available templates included only
the first hundreds of amino acids, making modeling at
position 454 impossible. We next aimed at assessing the
functional impact of the p.Thr454Met variant for (1)
secondary structure and (2) protein stability via PSIPRED
Protein Sequence Analysis Workbench27 and I-Mutant
2.0,28 respectively. Although these results did not show
a measurable effect of the p.Thr454Met variant on protein
stability, we did observe a more ‘‘disorganized’’ state and
an increased protein binding capacity27,29 for the corre-
spondingpart of theGRHL3protein (Figures 1 and S1, Table
S4). This strongly suggests a functional effect implicating
rs41268753 as a causative variant at the GRHL3 locus.
Given the evidence implicating a functional role for
rs41268753 in nsCPO, we then evaluated its possible role
in nsCL/P, using both the sequencing data generated in
the present study and imputed data from our large in-
house study that was comprised of 399 individuals with
nsCL/P and 1,318 control subjects.3 In our sequencing
study, the rs41268753 major (non-risk) allele was overrep-
resented in the nsCL/P group, when compared to the 267
Central European control subjects (p ¼ 6.31 3 102), and
similar results were obtained in the genome-wide imputed
nsCL/P data showing no association (p¼ 0.45). These find-The Amings indicate that rs41268753 does not confer an effect in
individuals with nsCL/P and is therefore the first risk locus
that uniquely contributes to nsCPO.
We hypothesized that common variant(s) located in the
regulatory region up- or downstream of GRHL3might also
contribute to either nsCL/P or nsCPO. This would parallel
the situation described for IRF6, where the promoter
variant rs642961 upstream of IRF6 affects binding of
the transcription factor AP2alpha and increases risk for
nsCL/P.9 We therefore analyzed the imputed data from
both genome-wide datasets on nsCL/P3 and nsCPO10
for the GRHL3 coding region (GenBank: NM_198174.2;
chr1: 24,645,812–24,690,970) up to5 200 kb. All variants
with SNP info scores > 0.4 and a MAF > 1% were ex-
tracted and plotted with LocusZoom,30 which resulted in
1,401 variants for nsCL/P and 1,379 variants for nsCPO
(Figure S2). In nsCL/P, the lowest p value observed was
p ¼ 0.0024 for rs4648988, located in the adjacent NIPAL3
gene. This association did not withstand correction for
multiple testing, suggesting that common variants at the
GRHL3 locus do not contribute to nsCL/P etiology. For
nsCPO, the coding variant rs41268753 described above
provided the strongest association, followed by a second
variant, rs113965554, that is in high linkage disequi-
librium (r2 > 0.8, Figure S2). The latter is located within
an intron of the adjacent STPG1 gene (MIM: 615826),
which could indicate a regulatory effect. Notably, neither
rs41268753 nor rs113965554 were present on any of the
genome-wide arrays used for nsCPO genotyping so far,
potentially explaining why the locus had not been de-
tected up to now. However, the comprehensive annotationerican Journal of Human Genetics 98, 755–762, April 7, 2016 757
Figure 1. Analysis of the Effect of
rs41268753 on the Disorganized Protein
State for GRHL3
Using DISOPRED3,26 the intrinsic disorder
profile for GRHL3 was generated for the
wild-type variant (A) and the variant
version p.Thr454Met (B). Protein-binding
sites are also indicated within disordered
regions. The black line indicates the
variant position around which a set of 19
consecutive amino acids (positions 443 to
461) are newly annotated as ‘‘disordered’’
or ‘‘disordered protein binding,’’ suggest-
ing an increase of binding capacity for
that region.software RegulomeDB v.1.131 annotated rs113965554 with
a score of 6, thus not indicating a regulatory effect. Collec-
tively, our data do not support an association of regulatory
common variants at the GRHL3 locus with nsCPO.
Apart from the common variants, our sequencing
approach in 672 Central European individuals with non-
syndromic clefting identified 18 rare variantswith allele fre-
quencies below 1% (Table S2), six of them not listed
indbSNP142.Among these six variantswere fournovel (un-
listed in EVS, 1000 Genomes, ExAC, or GoNL) truncating
GRHL3mutations in four index individuals from unrelated
families, ofwhich twooccurred denovo (Table 2, Figure S3).
Three of these novel variants were splice site mutations
occurring in three unrelated individuals with nsCPO (Table
S2). For variant c.840þ1G>T (p.?) (family BN-042), analysis
of parental DNA revealed de novo occurrence in the index
individual. Variant c.738C>T (family BN-248) is a synony-
mous variant (p.Gly246¼) creating a cryptic splice site as
suggested in silico by the splice site prediction NNSPLICE
v.0.9.32 It occurred de novo in the mother and was
transmitted to her daughter, and both were affected with
nsCPO (Figure S3). Transcript analysis in blood confirmed
the biological effect of the predicted splice site mutation
(data not shown). In both families with de novomutations,
paternity was confirmed using a set of 16 microsatellites
(PowerPlex 16 HS, Promega). In family BN-813, we identi-
fied c.1285þ2delT (p.?), which is predicted to affect a
splice donor site and was present in three affected in-
dividuals, i.e., two half-sisters and their mother (Figure 2).
In a fourth family (BN-912), a frameshift mutation
(c.916dupC [p.Arg306Profs*11]) was identified in two
affectedbrothers and their affectedmother,whereas theun-
affected brother did not carry this variant. In addition, a
missense mutation (c.937C>T [p.Arg313Trp], Table S2)
classified as ‘‘probably damaging’’ (PolyPhen-2) and ‘‘dele-
terious’’ (SIFT) was identified in an individual with no
affected relatives. This variant was not listed in any of the
queried databases, but segregation analysis detected the
variant also in the unaffected mother and sibling. There-
fore, although it is not clear whether this variant can be
causal but with reduced penetrance, this is similar to find-
ings reported for VWS in three of the eight families
described by Peyrard and colleagues.15 In index individual
BN-136, a variant (c.17þ93G>A [p.?])was identified,which758 The American Journal of Human Genetics 98, 755–762, April 7, 2is an intronic variant in two GRHL3 isoforms and
located in the UTR of one further isoform (GenBank:
NM_001195010.1). This and the fact that this variant is
also present in the unaffected mother suggests that it is
not causative.
In contrast to the mutations described in VWS-affected
individuals, which are distributed overGRHL3, all probably
pathogenic (i.e., truncating) mutations and the missense
mutation of yet unknown significance identified in our in-
dividuals with nonsyndromic clefting were located within
the GRHL3 DNA binding domain. Further investigation
will be required to determine whether or not this reflects a
genuine genotype-phenotype correlation.
Because a posteriori reviews of individuals harboring
IRF6 mutations in previous studies of individuals with
apparently nonsyndromic clefting have revealed unre-
ported lip pits (and thus misdiagnosed VWS-affected
families),17 we personally re-visited all affected members
of the four families with truncating mutations. Accord-
ing to the initial clinical data available at time of recruit-
ment, eight of the nine individuals harboring mutations
had an isolated cleft palate, and one (BN-813-II-5) was
reported to be unaffected (Figure 2). Initial reports on
affected oral structures were confirmed where four indi-
viduals had a cleft soft palate and four had a cleft hard
and soft palate. None of these individuals showed the
typical lip pits seen with VWS or even minor forms,
which we also confirmed in available pre-operative pho-
tographs, and lip pits in relatives were denied. Notably,
upon revisiting, family member BN-813-II-5 (initially
reported to be unaffected) was found to have a broad
uvula and nasal speech strongly suggestive of a sub-
mucous palatal cleft. Interestingly, her daughters (who
were half-sisters BN-813-III-7 and BN-813-III-8), showed
slightly asymmetrical lower lips with elevations on the
left side when opening their mouths (Figure 2). Without
a molecular diagnosis, this very subtle symptom would
not have indicated VWS. However, these elevations
might represent very subtle forms of lower lip pits or
transverse sulci, which also have been described in
VWS-affected subjects,33 so a posteriori this might be
called a ‘‘transitional’’ phenotype. Therefore, the combi-
nation of thorough clinical and genetic assessment re-
vealed potentially important findings with implications016
Table 2. Overview of GRHL3 Truncating Mutations in Individuals with nsCPO
Genomic
Position (hg19) cDNA Change Location
Protein Amino
Acid Change Functional Effect Status
24.664.177 c.738C>T exon 6 p.Gly246fs*10 introduces alternative splice donor sitea de novo
24.664.280 c.840þ1G>T intron 6 p.? splice donor site mutation de novo
24.664.557 c.916dupC exon 7 p.Arg306Profs*11 frameshift complete co-segregation
24.669.264 c.1285þ2delT intron 10 p.? splice donor site mutation complete co-segregation
None of the truncating variants was observed in any of the following databases: European population of 1000 Genomes phase 3, European variant server
(European Americans), Non-Finnish Europeans of the Exome Aggregation consortium, or Genome of the Netherlands. Positions given for GenBank:
NM_198174.2, NP_937817.3. Pedigree information can be found in Figure S3.
aEffect at RNA level confirmed by cDNA sequencing.for counseling and diagnostics. Obviously GRHL3 muta-
tions are more implicated in ‘‘nonsyndromic’’ forms of
clefting than IRF6.
Another aspect concerns the family structure, where
three of the four families with truncating mutations had
two or three affected individuals in consecutive genera-
tions. In general, recurrence risks for nsCPO in first-degree
relatives are quite low (above 0.03),34 so multiply-affected
families remain quite rare for nsCPO. In this study, 27
of the 96 sequenced nsCPO index individuals have one
or more affected relative(s) (defined as a first-, second-,
or third-degree relative), which is higher than in the
average population and therefore represents an ascertain-
ment bias. Our data allow for a preliminary assump-
tion of the frequency of truncating GRHL3 mutations
among nsCPO-affected individuals where the a priori
(i.e., without knowledge of family history) chance to iden-
tify a GRHL3 mutation in individuals with nsCPO can be
estimated as 0.017 (calculated by adding the estimated
chance that an individual with an nsCPO is sporadic
and has a GRHL3 mutation of 0.97 3 (1: 69), to the esti-
mated chance that an individual with an nsCPO has a
positive family history and a GRHL3 mutation of 0.03 3
(3: 27)). This is lower than the reported frequency of
causative GRHL3 mutations in VWS of around 0.05.15
However, nsCPO has a frequency of around one in
2,400,2 whereas VWS has been estimated to account for
roughly one in 30,000 to one in 100,000 in the European
and Asian populations (see GeneReviews in Web Re-
sources). Based on these estimates, in the general pop-
ulation one in 141,000 people has a GRHL3 mutation
with an apparent nonsyndromic CPO, and only one in
600,000 to one in 2,000,000 has a GRHL3-related VWS-
CPO, i.e., individuals with GRHL3 mutations with an
apparent nonsyndromic CPO should outnumber GRHL3-
related VWS-CPO-affected subjects by around 4 to 14.
Thus, GRHL3 mutations, initially identified from study
of a syndrome, might in fact more often lead to an iso-
lated, nonsyndromic cleft. Similar observations have
also been made for other genes, for example for CEP290
(MIM: 610142), initially identified as a gene underlying
a form of Joubert syndrome, which is associated in all pa-
tients with congenital amaurosis, and was later identifiedThe Amas a frequent cause of isolated Leber congenital amau-
rosis.36
As a result of our sequencing study, we report here on an
autosomal dominantly inherited form of clefting in indi-
viduals with nsCPO, which has important implications
for genetic counseling. For individuals with an nsCPO,
and especially in those with a positive family history, the
option of GRHL3 mutation screening should be discussed
when affected individuals ask for cleft risks in their
offspring. Of note, the four families identified with trun-
cating mutations in this study have up to three affected
family members. It is quite conceivable that in these fam-
ilies some descendants will have lip pits and/or a CL/P,
changing the clinical diagnosis for the family from ‘‘truly
nonsyndromic’’ to ‘‘VWS.’’ Unless proven otherwise, indi-
viduals with GRHL3 mutations, regardless of whether
apparently ‘‘nonsyndromic’’ or not, should be counseled
for a considerably higher cleft recurrence risk with the po-
tential for other VWS symptoms such as lip pits in their
offspring. In other words, individuals with GRHL3 muta-
tions and nsCPO will potentially have a higher recurrence
risk for a cleft lip and lip pits in their offspring. The risk fig-
ures based on the VWS-affected families reported by
Peyrard et al.15 are from a very limited number of observa-
tions, and our observations suggest that the true risks
might be lower. It is also not known whether these risk es-
timates even apply to the ‘‘nonsyndromic’’ cleft individual
with a GRHL3 mutation. It will therefore be very valuable
to perform further sequencing studies on individuals
with nonsyndromic clefting, especially multiplex families,
taking great care to carefully phenotype individuals with a
GRHL3 mutation.
In summary, we identified both rare dominant muta-
tions and a common risk variant in the coding region of
GRHL3 as causative in individuals with nsCPO. At a more
general level, our results demonstrate that a proportion
of nsCPOs will represent a variety of monogenic syn-
dromic forms, but with reduced penetrance of accompa-
nying symptoms. This hypothesis is supported by the
observation that GWASs and other genetic studies on
nsCPO have so far lacked any convincing association find-
ings, despite reasonable sample sizes, in particular when
compared to nsCL/P. Systematic sequencing approacheserican Journal of Human Genetics 98, 755–762, April 7, 2016 759
Figure 2. A GRHL3 Mutation in a Family
with Three Individuals Affected by CPO,
Two of Them with Asymmetrical Lower
Lips, which Might Represent a Subtle
VWS Symptom
(A) In BN-813-III-7 we identified
c.1285þ2delT, predicted to affect a splice
donor site. This variant was also identified
in the half-sister (BN-813-III-8) and in the
mother (BN-813-II-5), but was not present
in the half-sister’s father (BN-813-II-6). No
DNA from BN-813-I-1 or BN-813-I-2 was
available for analysis. Both half-sisters had
a complete cleft of the hard and soft palate.
Of note, the mother was initially reported as unaffected, but at clinical re-examination was found to have a broad uvula and had nasal
speech that was strongly suggestive of a submucous cleft palate. None of the three affected individuals showed the VWS typical lip pits.
(B and C) Both half-sisters BN-813-III-7 (B) and BN-813-III-8 (C) showed slightly asymmetrical lower lips with elevations on the left side
when opening their mouths. Given their molecular diagnosis, these elevations might a posteriori be interpreted as a very subtle form of
either lower lip pits or transverse sulci of the lips, symptoms occasionally described in VWS.such as exome or genome sequencing are likely to play an
important role in the delineation of further monogenic
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